Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02919969 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Metastatic Anal Cancer
A Phase 2 study of Anal Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 4
- Study locations
NCT02919969 is a Phase 2 study of Anal Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 38 participants, below the 578-participant average among 19 other Anal Cancer trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT02919969, a Phase 2 study of Anal Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study is studying a targeted therapy as a possible treatment for advanced anal cancer. The following intervention will be involved in this study: -Pembrolizumab
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (4)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-10-11 |
| Est. Completion | 2023-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02919969
The ClinicalTrials.gov registry entry for NCT02919969 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 578-participant average among 19 other Anal Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02919969 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Washington.
Frequently Asked Questions
What is clinical trial NCT02919969 about?
NCT02919969 is a clinical study titled "Pembrolizumab in Metastatic Anal Cancer". This research study is studying a targeted therapy as a possible treatment for advanced anal cancer. The following intervention will be involved in this study: -Pembrolizumab
What is the current status of trial NCT02919969?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2016-10-11. Estimated completion is 2023-03.
What conditions does trial NCT02919969 study?
This clinical trial studies the following conditions: Anal Cancer.
What interventions are being tested in trial NCT02919969?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02919969?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02919969 being conducted?
This trial has 4 study locations across Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
RECRUITING · Phase 2
-
REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
ACTIVE NOT RECRUITING · Phase 2
-
Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer
COMPLETED · Phase 2
-
Assessing THE GAY Male Experience With Anal Cancer Prevention Strategies
RECRUITING
-
Self-sampling to Optimize Anal Lesion Outcomes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.